- Home
- CENX vs GNLX Comparison
CENX vs GNLX Comparison
Compare CENX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENX
- GNLX
- Stock Information
- Founded
- CENX 1995
- GNLX 2001
- Country
- CENX United States
- GNLX United States
- Employees
- CENX N/A
- GNLX N/A
- Industry
- CENX Aluminum
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CENX Industrials
- GNLX Health Care
- Exchange
- CENX Nasdaq
- GNLX Nasdaq
- Market Cap
- CENX 1.8B
- GNLX 96.6M
- IPO Year
- CENX 1996
- GNLX 2023
- Fundamental
- Price
- CENX $18.02
- GNLX $2.87
- Analyst Decision
- CENX Strong Buy
- GNLX Strong Buy
- Analyst Count
- CENX 3
- GNLX 4
- Target Price
- CENX $23.00
- GNLX $17.75
- AVG Volume (30 Days)
- CENX 1.8M
- GNLX 151.1K
- Earning Date
- CENX 08-07-2025
- GNLX 08-13-2025
- Dividend Yield
- CENX N/A
- GNLX N/A
- EPS Growth
- CENX N/A
- GNLX N/A
- EPS
- CENX 1.22
- GNLX N/A
- Revenue
- CENX $2,364,700,000.00
- GNLX N/A
- Revenue This Year
- CENX $7.19
- GNLX N/A
- Revenue Next Year
- CENX $3.99
- GNLX N/A
- P/E Ratio
- CENX $14.79
- GNLX N/A
- Revenue Growth
- CENX 11.41
- GNLX N/A
- 52 Week Low
- CENX $11.40
- GNLX $1.60
- 52 Week High
- CENX $25.39
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CENX 53.93
- GNLX 52.48
- Support Level
- CENX $16.90
- GNLX $2.75
- Resistance Level
- CENX $17.89
- GNLX $3.17
- Average True Range (ATR)
- CENX 0.75
- GNLX 0.25
- MACD
- CENX -0.19
- GNLX 0.01
- Stochastic Oscillator
- CENX 43.19
- GNLX 44.74
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.